Literature DB >> 18601850

[Effects of gastrodin injection on blood pressure and vasoactive substances in treatment of old patients with refractory hypertension: a randomized controlled trial].

Qin Zhang1, Yun-mei Yang, Guo-you Yu.   

Abstract

OBJECTIVE: To examine and determine the contents of endothelin (ET) and nitric oxide (NO) in plasma, and to observe the effects of gastrodin injection on blood pressure, ET and NO levels in old patients with refractory hypertension.
METHODS: A total of 63 old patients with refractory hypertension, 30 patients with common hypertension and 30 healthy people were included. The contents of ET and NO in plasma of patients in different groups and healthy people were examined and analyzed. The old patients with refractory hypertension were randomly divided into two groups: gastrodin-treated and routine treatment groups. Besides conventional hypotensive drugs, intravenous drip infusion of 1 000 mg gastrodin was administered to the patients in gastrodin-treated group for two courses (4 weeks), while the patients in routine treatment group were treated only with conventional hypotensive drugs. The changes of blood pressure, ET and NO levels before and after treatment in different groups were measured.
RESULTS: The plasma level of ET in refractory hypertension group was higher than that in common hypertension group (t=3.27, P=0.008), while the level of NO was lower (t=-3.81, P=0.002). The systolic pressure and pulse pressure difference in gastrodin-treated group were decreased significantly after one course of treatment (t=1.85, P=0.03; t=1.74, P=0.04). The level of ET in gastrodin-treated group decreased gradually after treatment, but there were no significant difference between before treatment and two courses of treatment, while the level of NO in gastrodin-treated group was increased after treatment (t=-2.70; P=0.04).
CONCLUSION: Gastrodin injection is beneficial to old patients with refractory hypertension, and can improve the balance of ET and NO levels in plasma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18601850     DOI: 10.3736/jcim20080707

Source DB:  PubMed          Journal:  Zhong Xi Yi Jie He Xue Bao        ISSN: 1672-1977


  13 in total

1.  Gastrodin protects against cardiac hypertrophy and fibrosis.

Authors:  Chunming Shu; Changgui Chen; Da-Ping Zhang; Haipeng Guo; Heng Zhou; Jing Zong; Zhouyan Bian; Xuan Dong; Jia Dai; Yan Zhang; Qizhu Tang
Journal:  Mol Cell Biochem       Date:  2011-07-16       Impact factor: 3.396

2.  The Potential Role of PKA/CREB Signaling Pathway Concerned with Gastrodin Administration on Methamphetamine-Induced Conditioned Place Preference Rats and SH-SY5Y Cell Line.

Authors:  Gen-Meng Yang; Lu Li; Feng-Lin Xue; Chen-Li Ma; Xiao-Feng Zeng; Yong-Na Zhao; Dong-Xian Zhang; Yang Yu; Qian-Wen Yan; Yi-Qing Zhou; Shi-Jun Hong; Li-Hua Li
Journal:  Neurotox Res       Date:  2020-01-04       Impact factor: 3.911

Review 3.  Chinese herbal medicine for resistant hypertension: a systematic review.

Authors:  Xingjiang Xiong; Xiaoke Li; Yuqing Zhang; Jie Wang
Journal:  BMJ Open       Date:  2015-01-30       Impact factor: 2.692

Review 4.  Anti-Hypertensive Herbs and Their Mechanisms of Action: Part II.

Authors:  M Akhtar Anwar; Sara S Al Disi; Ali H Eid
Journal:  Front Pharmacol       Date:  2016-03-08       Impact factor: 5.810

5.  Gastrodin alleviates inflammatory injury of cardiomyocytes in septic shock mice via inhibiting NLRP3 expression.

Authors:  Feifei Shao; Lingmin Zhou; Yu Zhang; Hongping Chen; Yu Zhang; Zhihui Guan
Journal:  In Vitro Cell Dev Biol Anim       Date:  2021-06-09       Impact factor: 2.416

6.  Gastrodin Exerts Cardioprotective Action via Inhibition of Insulin-Like Growth Factor Type 2/Insulin-Like Growth Factor Type 2 Receptor Expression in Cardiac Hypertrophy.

Authors:  Jun Lu; Xin Ma; Wen-Cong Gao; Xin Zhang; Yuanling Fu; Qian Liu; Lixiang Tian; Xiao-Dan Qin; Weimin Yang; Hong-Yi Zheng; Chang-Bo Zheng
Journal:  ACS Omega       Date:  2021-06-21

7.  Gastrodin protects apoptotic dopaminergic neurons in a toxin-induced Parkinson's disease model.

Authors:  Hemant Kumar; In-Su Kim; Sandeep Vasant More; Byung-Wook Kim; Young-Yil Bahk; Dong-Kug Choi
Journal:  Evid Based Complement Alternat Med       Date:  2013-03-03       Impact factor: 2.629

8.  Gastrodin Reduces Blood Pressure by Intervening with RAAS and PPARγ in SHRs.

Authors:  Wei Liu; Lingyan Wang; Jiahui Yu; Patrick Fordjour Asare; Ying-Qiang Zhao
Journal:  Evid Based Complement Alternat Med       Date:  2015-10-26       Impact factor: 2.629

Review 9.  A Review on Central Nervous System Effects of Gastrodin.

Authors:  Yuan Liu; Jialiang Gao; Min Peng; Hongyan Meng; Hongbo Ma; Pingping Cai; Yuan Xu; Qiong Zhao; Guomin Si
Journal:  Front Pharmacol       Date:  2018-02-02       Impact factor: 5.810

10.  The effects of gastrodin injection on hypertension: A systematic review and meta-analysis.

Authors:  Lichao Qian; Shihai Yan; Yizhuo Li; Lihua Wu; Yawei Zheng; Yixuan Wang; Zhuyuan Fang
Journal:  Medicine (Baltimore)       Date:  2020-07-02       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.